Research Article

Surgical Implantation of Stem Cells in Heart Failure Patients due to Idiophatic Cardiomyopathy

Benetti Federico*, Natalia Scialacomo, Enrique Mariani, Luis Geffner, Bruno Benetti Eng1, Daniel Brusich and Yan Duarte

Published: 25 July, 2017 | Volume 1 - Issue 1 | Pages: 017-027

Introduction: Congestive heart failure is one of the main causes of morbidity and mortality in the XXI century given the promising to date of ABMDSCs and HFDSCs we investigate the safety and efficacy for the implantation of those stem cells for the treatment of idiopathic cardiomyopathy. This is the first pilot clinical study to assess the safety and feasibility of HFDSC in humans. We totally implanted 13 patients: 3 patients were implanted with ABMDSC by Mini-invasive surgical technique in March 2004 in Montevideo, Uruguay, and 10 patients were implanted with HFDSCs by using 2 different surgical techniques: minimally invasive technique (1 patient) and full sternotomy technique (9 patients) between January and February of 2005 in Guayaquil Ecuador.

The HFDSCs were obtained from fetuses of 5 to 12 weeks´ gestation from legally consent, no compensated donors who have undergone terminated ectopic pregnancies, elective abortions, or spontaneous miscarriages. At that gestation´s period, totipotent stem cells´ fetus haven´t develop yet the HLA histocompatibility complex, so there´s no possible antigenicity between donor and recipient.

Results: Patients with HFDSCs improved in association with increased contractility in these regions. Compared with baseline assessments, we noted other improvements: The mean (±SD) NYHA class decreased from 3.4±0.5 to 1.33±0.5 (P=.001); the mean EF increased 31%, from 26.6% ± 4.0% to 34.8%±7.2% (P=.005); performance in the ETT increased 291.3%, from 4.25 minutes to 16.63 minutes (128.9% in metabolic equivalents, 2.45 to 5.63) (P<.0001); the mean LVEDD decreased 15%, from 6.85±0.6cm to 5.80±0.58cm (P<.001); mean performance in the 6-minute walk test increased 43.2%, from 251±113.1 seconds to 360±0 seconds (P=.01); the mean distance increased 64.4%, from 284.4±144.9m to 468.2±89.8m (P=.004); and the mean result in the Minnesota congestive HF test decreased from 71±27.3 to 6±5.9 (P<.001) The Kaplan-Maier probability of survival at 48 months was 66%.

It is not observed rejection, these patients have not developed malignance nodules or cancer at all in the follow-up. In the AMBCSs. The preoperative average NYHA functional class was 3.4; at. 6 months of follow up the average functional class value was 1.3 (p<0,005);. After 6 months all of them remained in functional class I/II. Baseline values of LVEF were 25,28 and 30%.; at 6 months increased to 38, 40 and 46%. (p<0,05). LVESV went from 50mm to 42mm (p<0.05). After 24 months, 2 of the patients still maintained this improvement, while the 3er patient returned to the earlier values after suffering from pneumonia. At 12 years and 5 months 2 patients are alive both received a Resynchronization Therapy; at 8 years and 3 months and 9 years and 1,6 month the actual average EF are 28 and 30 %. The 3er patient died of sudden death at 10 years after the implantation. We can´t demonstrate the cause of this sudden death.

Conclusion: Irrespective of the improvement seen in this study, it is still premature to determine accurately the mechanism of action, indications, doses and type of stem cells. Therefore, is imperative and extremely important that more research is needed.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001003 Cite this Article Read Full Article PDF


Stem cells in heart failure patients; Heart failure patients due to Idiophatic Myocadiophaty treat with stem cells; Autologous stem cells in heart failure patients; Embriofetals cells in heart failure patients


  1. Remme WJ, Swedberg K. (co-chairman) Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal. 2001; 22: 1527-1560.
  2. ColucciW, Braunwald E. Patophysiology of Heart Failure, en Heart Disease de Braunwald. 5a Edición. 1997; 360-393.
  3. Enrique V. Carbajal, MD, Prakash C. Deedwani A. Current Diagnosis and Treatment is Cardiology 2nd Ed. Congestive Heart Failure. 2003; 18.
  4. Bolling SF, Pagani FD, Deeb GM. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998; 115: 381-386. Ref.: https://goo.gl/geKzeF
  5. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac cardiovasc Surg. 2000; 120: 999-1005. Ref.: https://goo.gl/Jo188c
  6. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9: 702-712. Ref.: https://goo.gl/Kc6RFi
  7. Orlic D, Kassutra J, Chimenti S, Jakoniuk I, Anderson SM, et al. Bone marrow cells regenerate infracted myocardium. Nature 2001, 410: 701-705. Ref.: https://goo.gl/2Cp3yv
  8. Edelberg JM, Tang L, Hattori K, Lyden D, Rafi S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002; 90: 89-93. Ref.: https://goo.gl/Zs9skw
  9. Shi Q, Rafi S, Wu MH, Wijelath ES, Yu C, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362-367. Ref.: https://goo.gl/jkEvzJ
  10. Sata M, Saiura A, Kunisato A, Tojo A, Okara S, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403-409. Ref.: https://goo.gl/FXaqQG
  11. Otani A, Kinder K, Ewalt K, Otero S, Tokuhisa T, et al. Bone marrow derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002; 8: 1004-1010. Ref.: https://goo.gl/f6kA4G
  12. Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA. 2002; 99: 11951-11956. Ref.: https://goo.gl/sybF7H
  13. O´Donoghue K, Fisk NM. Fetal stem cells. Best Practice residential clinical Obstetric-Gynecologist. 2004; 18: 853-875.
  14. Touraine JL. Induction of the transplantation tolerance in humans using stem cells transplants prenatally or postnatally. Transplant Proc. 1999; 31: 2735-2737. Ref.: https://goo.gl/RVwoJr
  15. Tsymbalyuk VI, Yaminsky YY. Usage of embryonic nerve tissue transplantation to improve the conductivity of spinal cord after traumatic damage in animals and humans. Transplant ology. 2003; 4: 199-201.
  16. Zorin MO, Yurchenko TN, Latyshev DY. Application of cryopreserved suspension of embryonic neural cells in combined treatment of patients with ischemic insults of basal ganglia. Transplant ology. 2003; 4: 149-150.
  17. Salogub TV. Perspective of embryonic cell transplantation when treating patients wth epileptiform neuralgia of peripheral genesis. Transplant ology. 2003; 4: 184-185.
  18. Grischenko VI, Bobirova LE, Dvornek IL, Bovirova VM. Use of biotechnology in treatment of type I diabetes. Transplant ology. 2003; 4: 16-19.
  19. Meerson FZ. The myocardium in hyperfunction, hypertrophy and heart failure. Circ Res. 1969; 25. Ref.: https://goo.gl/ZVNtdb
  20. Zak R. Cardiac hypertrophy: biochemical and cellular relationships. Hosp Pract. 1983; 18: 85-97. Ref.: https://goo.gl/hcm5Eh
  21. Prosper F, Pérez A, Merino J, Gregorio Rábago, Juan Carlos Chachques, et al. Adult stem cells for myocardial repair. Basic Appl Myol. 2003; 13: 15-22. Ref.: https://goo.gl/meu43g
  22. Colucci WS, Braunwald E. Pathophysiology of heart failure in Braunwald¨s Heart Disease 5th edition Saunders company 1997.
  23. Prokop D. Marrow Stromal cells as Stem Cells for no hematopoietic tissues. Science. 1997; 276: 71-76. Ref.: https://goo.gl/eFLtnm
  24. Pittenger MF, Makay A, Beck SC, Jaiwasal RK, Douglas R, et al. Multiline age potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-147. Ref.: https://goo.gl/ewfT67
  25. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999; 105: 697-705. Ref.: https://goo.gl/zkqWyN
  26. Xu M, Wani M, Dai YS, Wang J, Yan M, et al. Differentiation of bone marrow stromal cells into cardiac phenotype requires intracellular communication with myocytes. Circulation. 2004; 110: 2658-2665. Ref.: https://goo.gl/5AS3NP
  27. Chedrway EG, Wang JS, Nguyen DM, shum-Tim J, Chiu RCJ. Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: anatomic basis for functional improvements. J Thorac Cardiovasc Surg. 2002; 124: 584-590. Ref.: https://goo.gl/TsAqpV
  28. Pittenger MF, Bradley JM. Mesenchymal stem cells and their potential as cardiac therapeutics. Circulation research. 2004; 95. Ref.: https://goo.gl/KCja9d
  29. Vilas-Boas F, Soares G, Sooare MB, Joel Alves Pinho-Filho; Augusto Mota, et al. Bone marrow cell transplantation to the myocardium of a patient with heart failure due to Chagas disease. Arq Bras Cardiol. 2004; 82: 185-187. Ref.: https://goo.gl/4vGjTx
  30. Benetti F, Viña RF, Patel AN. OPCABG plus simultaneous autologous stem cells implants. 2003.
  31. Patel AN, Geffner L, Vina RF, Jorge Saslavsky, Harold Urschel C, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thorac Cardiovasc Surg. 2005; 130: 1631-1638. Ref.: https://goo.gl/jXCi51
  32. Benetti F MD, Peñherrera E, Maldonado T, Vera YD, Subramanian V, et al. Direct Myocardial Implantation of Human Fetal Stem Cells in Heart Failure Patients: Long-term Results. The Heart Surgery Forum. 2010; 13: 31-35. Ref.: https://goo.gl/QsA7Lu


Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?